Susan Robson

1.2k total citations · 1 hit paper
17 papers, 826 citations indexed

About

Susan Robson is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology. According to data from OpenAlex, Susan Robson has authored 17 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Genetics and 5 papers in Hematology. Recurrent topics in Susan Robson's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Hemophilia Treatment and Research (5 papers). Susan Robson is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Hemophilia Treatment and Research (5 papers). Susan Robson collaborates with scholars based in Switzerland, Spain and Italy. Susan Robson's co-authors include Stephanie A. Amiel, Jane Speight, Carla Gianfrancesco, Lynn D. Newton, Simon Heller, Eileen Turner, Lindsay Oliver, Carolin Taylor, Sue Roberts and Peter James and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Susan Robson

15 papers receiving 773 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes : dose adjustment for normal eating (DAFNE) randomised controlled trial

2002 562 citations Stephanie A. Amiel, Clare Bradley et al. Deakin Research Online (Deakin University) profile →

Peers

Countries citing papers authored by Susan Robson

Since Specialization

Citations

This map shows the geographic impact of Susan Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Robson more than expected).

Fields of papers citing papers by Susan Robson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Robson. The network helps show where Susan Robson may publish in the future.

Co-authorship network of co-authors of Susan Robson

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Robson. A scholar is included among the top collaborators of Susan Robson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Robson. Susan Robson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study 2025 ·Haemophilia ·Jan Astermark, Susanna Ranta, (unknown), (unknown), Stéphane Quéré, (unknown), Susan Robson, (unknown), Riitta Lassila, Pål André Holme	0
2	Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors 2024 ·SHILAP Revista de lepidopterología ·Giancarlo Castaman, Flora Peyvandi, Johanna A. Kremer Hovinga, Roger E. G. Schutgens, Susan Robson, (unknown), Víctor Jiménez‐Yuste	5
3	Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY) 2022 ·Research and Practice in Thrombosis and Haemostasis ·Víctor Jiménez‐Yuste, Flora Peyvandi, Robert Klamroth, Giancarlo Castaman, Chandrakala Shanmukhaiah, Savita Rangarajan, (unknown), Raúl Martínez‐Fernández, Gili Kenet, (unknown), Susan Robson, Christophe Schmitt, Anna Kiialainen, Oliver Meier, Margareth C. Ozelo	29
4	Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study 2021 ·Haematologica ·Simon Rule, Wolney Barreto, Javier Briones, Angelo Michele Carella, Olivier Casasnovas, Chris Pocock, Clemens‐Martin Wendtner, Francesco Zaja, Susan Robson, Lachlan MacGregor, (unknown), (unknown), Martin Dreyling	3
5	Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors 2021 ·Hämostaseologie ·Víctor Jiménez‐Yuste, Robert Klamroth, Giancarlo Castaman, Johanna A. Kremer Hovinga, Chandrakala Shanmukhaiah, Savita Rangarajan, (unknown), Raúl Martínez‐Fernández, Gili Kenet, Susan Robson, Christophe Schmitt, Oliver Meier, Margareth C. Ozelo	2
6	Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis 2021 ·Blood ·Giancarlo Castaman, Jerzy Windyga, (unknown), Susan Robson, (unknown), Monet Howard, Víctor Jiménez‐Yuste	6
7	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study 2019 ·Leukemia ·Francesc Bosch, Guy Cantin, Agostino Cortelezzi, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, Andrey Zaritskey, (unknown), Eugen Tausch, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Sebastian Böttcher, Robin Foà, Stephan Stilgenbauer, Véronique Leblond	6
8	EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY 2019 ·Hematological Oncology ·Simon Rule, Wolney Barreto, Javier Briones, (unknown), Olivier Casasnovas, Christopher Pocock, Clemens‐Martin Wendtner, Francesco Zaja, Susan Robson, (unknown), Martin Dreyling	0
9	S101 EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: RESULTS OF THE PHASE III MABCUTE STUDY 2019 ·HemaSphere ·Simon Rule, Wolney Barreto, Javier Briones, (unknown), Christopher Pocock, C.‐M. Wendtner, Francesco Zaja, Susan Robson, (unknown), Martin Dreyling	2
10	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study 2018 ·Leukemia ·Stephan Stilgenbauer, Véronique Leblond, Robin Foà, Sebastian Böttcher, Osman İlhan, Wolfgang Knauf, Eva Ballová Mikušková, Christoph Renner, Eugen Tausch, Dariusz Woszczyk, Ekaterina Gresko, Linda Lundberg, Tom Moore, (unknown), Susan Robson, Francesc Bosch	20
11	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study 2018 ·Haematologica ·Véronique Leblond, Melih Aktan, (unknown), Caroline Dartigeas, Jens Kisro, Marco Montillo, João Raposo, (unknown), Susan Robson, Ekaterina Gresko, Francesc Bosch, Stephan Stilgenbauer, Robin Foà	13
12	Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials 2017 ·Blood ·Magdalena Klánová, Mikkel Z. Oestergaard, Marek Trněný, Wolfgang Hiddemann, Robert Marcus, Laurie H. Sehn, Umberto Vitolo, Alexandra Bazeos, Valentin Goede, Harald Zeuner, Andrea Knapp, (unknown), (unknown), Christopher R. Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle‐Rowson	2
13	Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study 2016 ·Annals of Oncology ·Grant A. McArthur, Michele Maio, Ana Arance, Paul Nathan, Christian U. Blank, Marie‐Françoise Avril, Claus Garbe, Axel Hauschild, Dirk Schadendorf, Omid Hamid, Michael Fluck, (unknown), Jacob Schachter, Richard Kefford, Marc C. Chamberlain, Martina Makrutzki, Susan Robson, René González, Kim Margolin	168
14	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study 2016 ·Blood ·Eli L. Diamond, Vivek Subbiah, (unknown), Jean‐Yves Blay, Jason E. Faris, Igor Puzanov, Ian Chau, Noopur Raje, (unknown), (unknown), Jean Torrisi, Gary A. Ulaner, Mario E. Lacouture, Susan Robson, Martina Makrutzki, Élena Elez, Josep Tabernero, Omar Abdel‐Wahab, José Baselga, David M. Hyman	3
15	Grasping the Nettle: Conflict and the Quaker Condition 2010 ·Susan Robson	1
16	Predicting outcomes in the dose adjustment for normal eating (DAFNE) trial 2005 ·Deakin Research Online (Deakin University) ·Jane Speight, (unknown), (unknown), Clare Bradley, Carla Gianfrancesco, Simon Heller, Prince James, (unknown), Lindsay Oliver, (unknown), Sue Roberts, Susan Robson, (unknown), (unknown), Carolin Taylor, (unknown), Eric E. Turner, Frances Wright	4
17	Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes : dose adjustment for normal eating (DAFNE) randomised controlled trial breakdown → 2002 ·Deakin Research Online (Deakin University) ·Stephanie A. Amiel, (unknown), Clare Bradley, Carla Gianfrancesco, Simon Heller, Peter James, (unknown), (unknown), Lynn D. Newton, Lindsay Oliver, (unknown), Sue Roberts, Susan Robson, (unknown), (unknown), Jane Speight, Carolin Taylor, (unknown), Eileen Turner, Frances Wright	562

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact